| Project/Area Number |
26293180
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nihon University (2016-2017)
Institute of Physical and Chemical Research (2014-2015) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
鈴木 康夫 東邦大学, 医学部, 教授 (40261911)
江崎 幹宏 九州大学, 大学病院, 講師 (50335957)
梅野 淳嗣 九州大学, 大学病院, 助教 (70621704)
LOW SIEWKEE 国立研究開発法人理化学研究所, 統合生命医科学研究センター, 研究員 (40634720)
|
|---|
| Research Collaborator |
MOTOYA Satoshi
FUYUNO Yuta
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2016: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2015: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
Fiscal Year 2014: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Keywords | 炎症性腸疾患 / 全ゲノム関連解析 / 薬剤応答性 / エピゲノム解析 / 薬剤反応性 |
|---|
| Outline of Final Research Achievements |
The aim of this project is to clarify the pathogenesis of inflammatory bowel disease (IBD) using by analysis of genome-wide genetic and epigenetic association. Since it is difficult to design using whole-genome epigenetic analysis for multifactorial disease except cancer, we focus the response of anti TNF-α monoclonal antibody in IBD. We have rescrueted patients with IBD who were treated with anti TNF-α antibody for the first time and examined methylation assays including whole-genome bisulfite sequncing.
Furthermore, we collaborated with the International IBD Genetics Consortium and conducted transancestry association study of IBD. Out trans-ethinic genome-wide association study clarified that the direction and magnitude of effect are consistent in European and non-European cohorts in spite of the genetic heterogeneity between divergent populations at several established risk loci driven by differences in allele frequency or effect size.
|
